Large-scale testing (Phase 3)Study completedNCT00150202What this trial is testingClinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)Who this might be right forMacular Degeneration Pfizer 90
Testing effectiveness (Phase 2)Study completedNCT00284089What this trial is testingSafety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationWho this might be right forSubfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) Novartis 88
Large-scale testing (Phase 3)Study completedNCT03844074What this trial is testingA Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)Who this might be right forAge-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration Outlook Therapeutics, Inc. 61
Large-scale testing (Phase 3)Study completedNCT04005352What this trial is testingStudy to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)Who this might be right forAge-related Macular Degeneration Novartis Pharmaceuticals 734
Not applicableStudy completedNCT00845273What this trial is testingLong-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular DegenerationWho this might be right forMacular Degeneration Pfizer 3,538
Large-scale testing (Phase 3)Study completedNCT00429962What this trial is testingStudy Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNVWho this might be right forChoroidal NeovascularizationAge-Related Macular Degeneration University Hospital, Basel, Switzerland 40
Large-scale testing (Phase 3)Study completedNCT00826371What this trial is testingEvaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) PatientsWho this might be right forAge Related Macular Degeneration Novartis Pharmaceuticals 114
Large-scale testing (Phase 3)Study completedNCT03834753What this trial is testingA Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)Who this might be right forAge-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration Outlook Therapeutics, Inc. 228
Large-scale testing (Phase 3)Study completedNCT00436553What this trial is testingEfficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationWho this might be right forMacular DegenerationChoroidal Neovascularization Novartis 321
Testing effectiveness (Phase 2)Study completedNCT00138632What this trial is testingSafety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)Who this might be right forWet Age-Related Macular Degeneration Novartis 50
Testing effectiveness (Phase 2)Study completedNCT00359164What this trial is testingPhase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.Who this might be right forMacular Degeneration University of British Columbia 36
Post-approval studies (Phase 4)Study completedNCT04679935What this trial is testingEfficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationWho this might be right forAge-related Macular Degeneration Novartis Pharmaceuticals 52
Post-approval studies (Phase 4)Study completedNCT00504959What this trial is testingSafety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationWho this might be right forSubfoveal Choroidal Neovascularization (CNV)Secondary to Age-related Macular Degeneration (AMD) Novartis 234
Testing effectiveness (Phase 2)Study completedNCT00363714What this trial is testingA Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)Who this might be right forAge-Related Macular DegenerationChoroidal Neovascularization Allergan 26
Early research (Phase 1)Study completedNCT00503022What this trial is testingSafety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular DegenerationWho this might be right forWet Age-Related Macular Degeneration Novartis 20
Testing effectiveness (Phase 2)Study completedNCT00239928What this trial is testingClinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular DegenerationWho this might be right forMacular Degeneration Pfizer 61
Post-approval studies (Phase 4)Study completedNCT01972789What this trial is testingComparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)Who this might be right forSubfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD Novartis Pharmaceuticals 349
Large-scale testing (Phase 3)Study completedNCT00121407What this trial is testingVisudyne® in Occult (VIO)Who this might be right forMacular Degeneration QLT Inc. 364
Large-scale testing (Phase 3)Study completedNCT00275821What this trial is testingEfficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)Who this might be right forAge Related Macular Degeneration Novartis 353
Testing effectiveness (Phase 2)Study completedNCT00288561What this trial is testingStudy of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular DegenerationWho this might be right forAge-Related Macular Degeneration (ARMD) Novartis